Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
I-CAN: GS-101 eye drops for inhibition of corneal neovascularization
2008-005388-33Phase 3Completed
- Sponsor
- Center for Testing and Research Services
- Start
- Oct 2008
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in corneal neovascularization (CNV), keratitis and keratouveitis comparing GS-101 eye drops with Placebo eye drops (2 arms). Primary endpoint: Visual acuity. Started Oct 2008; status: completed.
02
Drugs
aganirsen
03
Conditions
corneal neovascularization (CNV)keratitiskeratouveitis
Beyond the preview
Go deeper on 2008-005388-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-005388-33.